Tracking inflammation markers in people with Ph-negative myeloproliferative neoplasms over time
Observes inflammation markers in adults with Ph-negative myeloproliferative neoplasms and their disease course.
Plain-language title generated from the registry record
Registry title: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
Key facts
- Where
- Bari, Bologna, Brescia, Catania, Naples, Roma, Torino, Udine, Verona, and Viterbo, ItalySee the 11 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05553873, who can take part
Where in Italy
- Azienda Ospedaliera Universitaria Consorziale PoliclinicoBari, ItalyTaking people
- Policlinico Sant'Orsola-MalpighiBologna, ItalyTaking people
- ASST Spedali Civili di BresciaBrescia, ItalyTaking people
- Policlinico Vittorio EmanueleCatania, ItalyTaking people
- Ospedale Universitario Federico IINaples, ItalyTaking people
- Policlinico Umberto I - Università La SapienzaRoma, ItalyTaking people
- Azienda Ospedaliera Universitaria Città della Salute e delle ScienzaTorino, ItalyTaking people
- Ospedale San Luigi di Orbassano - Ospedale MaurizianoTorino, ItalyTaking people
- Azienda Ospedaliera Universitaria Friuli CentraleUdine, ItalyTaking people
- Azienda Ospedaliera Universitaria integrataVerona, ItalyTaking people
- Ospedale BelcolleViterbo, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Milano Bicocca
- Trial code
- NCT05553873
- Record updated
- 2 January 2024
- Original description
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratificationRead full original descriptionShow less
Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Inclusion: Age ≥ 18 years at the time of diagnosis of MPN Ph negative; Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000); Obtaining informed consent.
Exclusion: Life expectancy of less than 6 months; Accelerated phase myelofibrosis or MPN with signs of leukemic evolution.